Biotech entity
Every one of those 2 sits in a single category, pharma. Miplyffa is most often covered alongside Justin Renz, which appears in 1 of these 2 stories. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Miplyffa is most often covered alongside Justin Renz, which appears in 1 of these 2 stories. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window. We currently track 2 Biotech stories that mention Miplyffa, published between March 5, 2026 and March 8, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 48 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Miplyffa. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.
Source: finanznachrichten.de · Seeking Alpha
Miplyffa is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
